Document:

EX-4.6

 Exhibit 4.6 

SIXTH SUPPLEMENTAL INDENTURE 

Dated as of August 18, 2021 

to 
 INDENTURE 

Dated as of May 12, 2015 

THE CHEMOURS COMPANY, 
 THE
GUARANTORS PARTY THERETO, 
 U.S. BANK NATIONAL ASSOCIATION, 

as Trustee, 
 ELAVON FINANCIAL
SERVICES DAC, UK BRANCH, 
 as Paying Agent, 

and 
 ELAVON FINANCIAL SERVICES
DAC, 
 as Registrar and Transfer Agent 
  

 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	PAGE	 
	 ARTICLE I
	  	 	1	 
			
	 SECTION 1.01
	 	Definitions	  	 	1	 
		
	 ARTICLE II AMENDMENTS TO THE INDENTURE
	  	 	2	 
			
	 SECTION 2.01
	 	Amendments to the Indenture	  	 	2	 
		
	 ARTICLE III MISCELLANEOUS
	  	 	2	 
			
	 SECTION 3.01
	 	Ratification of Original Indenture; Supplemental Indenture Part of Original Indenture	  	 	2	 
	 SECTION 3.02
	 	Concerning the Trustee	  	 	2	 
	 SECTION 3.03
	 	Multiple Originals; Electronic Signatures	  	 	2	 
	 SECTION 3.04
	 	GOVERNING LAW	  	 	2	 

 SIXTH SUPPLEMENTAL INDENTURE, dated as of August 18, 2021 (this “Sixth Supplemental
Indenture”), to the Indenture, dated as of May 12, 2015 (the “Original Indenture”), among THE CHEMOURS COMPANY, a Delaware corporation (the “Company”), each of the subsidiary guarantors party thereto
or that becomes a guarantor pursuant to the terms of the Original Indenture (the “Guarantors”), U.S. BANK NATIONAL ASSOCIATION, a national banking association organized under the laws of the United States, as trustee (the
“Trustee”), ELAVON FINANCIAL SERVICES DAC, UK BRANCH, a limited liability company registered in Ireland with the Companies Registration Office (registered number 418442), with its registered office at Building 8, Cherrywood Business
Park, Loughlinstown, Dublin 18, D18 W319, Ireland acting through its UK Branch (registered number BR009373) from its offices at 125 Old Broad Street, Fifth Floor, London EC2N 1AR, United Kingdom, as paying agent (the “Paying
Agent”), and ELAVON FINANCIAL SERVICES DAC, a limited liability company registered in Ireland with the Companies Registration Office (registered number 418442), with its registered office at Building 8, Cherrywood Business Park,
Loughlinstown, Dublin 18, D18 W319, Ireland, as registrar (the “Registrar”) and transfer agent (the “Transfer Agent” and, together with the Paying Agent and the Registrar, the “Euro Agents”). 

WHEREAS, the Company, the Guarantors, the Trustee and the Euro Agents have heretofore executed and delivered the Original Indenture to provide for the
issuance from time to time of Notes of the Company, to be issued in one or more Series; 
 WHEREAS, the Company, the Guarantors party thereto and the
Trustee have heretofore executed and delivered the Second Supplemental Indenture (the “Second Supplemental Indenture”), dated May 12, 2015, to establish the form and terms of and to provide for the issuance of the
Company’s 7.000% Senior Notes Due 2025 (the “2025 Notes”); 
 WHEREAS, Section 9.02 of the Original Indenture provides, among
other things, that except as provided therein, the Company, the Guarantors and the Trustee may amend the Original Indenture, any Guarantee and the Notes (in each case with respect to one or Series of Notes) with the written consent of the Holders of
at least a majority in aggregate principal amount of the Notes of the applicable Series then Outstanding, including consents obtained in connection with a purchase of, or tender offer or exchange offer for the Notes; 

WHEREAS, the Company has heretofore obtained the written consent of the Holders of more than a majority in aggregate principal amount of the 2025 Notes to the
amendments described in Article II of this Sixth Supplemental Indenture; 
 WHEREAS, the Issuer has heretofore delivered to the Trustee the Officer’s
Certificate and Opinion of Counsel described in Sections 9.05, 11.04 and 11.05 of the Original Indenture; 
 WHEREAS, all action on the part of the Company
necessary to authorize the execution and delivery of this Sixth Supplemental Indenture have been duly taken; and 
 WHEREAS, pursuant to Section 9.02
of the Original Indenture, the Company, the Guarantors and the Trustee are authorized to execute and deliver this Sixth Supplemental Indenture (the Original Indenture, as supplemented by the Second Supplemental Indenture and this Sixth Supplemental
Indenture being hereinafter called the “Indenture”). 
 NOW, THEREFORE, THIS INDENTURE WITNESSETH: 

That, in consideration of the foregoing and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
parties hereto hereby agree as follows: 
 ARTICLE I 

SECTION 1.01. Definitions. 
 (a) Capitalized terms used
herein and not otherwise defined herein shall have the respective meanings ascribed thereto in the Original Indenture, as supplemented by the Second Supplemental Indenture. 

(b) The rules of interpretation set forth in the Original Indenture shall be applied hereto as if set forth in full herein. 

  
 1 

 ARTICLE II 

AMENDMENTS TO THE INDENTURE 
 SECTION 2.01.
Amendments to the Indenture. 
  

	 	(a)	 The first sentence of the first paragraph of Section 2.10(b) of the Second Supplemental Indenture shall be
deleted in its entirety and replaced with the following: 

 “On and after May 15, 2020, the Company may redeem
the Notes, in whole or in part, upon not less than 2 business days’ nor more than 60 calendar days’ notice, at the redemption prices (expressed as percentages of principal amount of the Notes to be redeemed) set forth below, plus accrued
and unpaid interest thereon, to the date of redemption (the “Redemption Date”), subject to the right of Holders of record on the relevant record date to receive interest due on the relevant interest payment date, if redeemed beginning on
May 15 of the years indicated below:” 
  

	 	(b)	 The second paragraph of Section 2.10(b) of the Second Supplemental Indenture shall be deleted in its
entirety and replaced with the following: 

 “Notwithstanding the foregoing, in connection with any tender offer for
all of the outstanding Notes at a price of at least 100% of the principal amount of the Notes tendered, plus accrued and unpaid interest thereon to, but excluding, the applicable tender settlement date (including any Change of Control Offer), if
Holders of not less than 90% in aggregate principal amount of the outstanding Notes validly tender and do not withdraw such Notes in such tender offer and the Company, or (in the case of a Change of Control Offer) any third party making such a
tender offer in lieu of the Company, purchases all of the Notes validly tendered and not validly withdrawn by such Holders, the Company or such third party will have the right, upon not less than 1 business day’s nor more than 60 calendar
days’ prior notice, given not more than 30 calendar days following such purchase date, to redeem all Notes that remain Outstanding following such purchase at a price equal to the price offered to each other Holder in such tender offer plus, to
the extent not included in the tender offer payment, accrued and unpaid interest, if any, thereon, to, but excluding, the Redemption Date.” 

ARTICLE III 
 MISCELLANEOUS 

SECTION 3.01. Ratification of Original Indenture; Supplemental Indenture Part of Original Indenture. Except as expressly amended hereby, the Original
Indenture, including Section 11.18 thereof regarding submission to jurisdiction, is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect. This Sixth Supplemental
Indenture shall form a part of the Original Indenture for all purposes, and every Holder of Notes heretofore or hereafter authenticated and delivered shall be bound hereby. 

SECTION 3.02. Concerning the Trustee. The recitals contained herein and in the 2025 Notes, except with respect to the Trustee’s certificates of
authentication, shall be taken as the statements of the Company, and the Trustee assumes no responsibility for the correctness of the same. The Trustee makes no representations as to the validity or sufficiency of this Sixth Supplemental Indenture
or of the 2025 Notes. 
 SECTION 3.03. Multiple Originals; Electronic Signatures. This Sixth Supplemental Indenture may be executed in any number of
counterparts, each of which when so executed shall be deemed to be an original, but all such counterparts shall together constitute one and the same instrument. The exchange of copies of this Sixth Supplemental Indenture and of signature pages by
facsimile or PDF transmission shall constitute effective execution and delivery of this Sixth Supplemental Indenture as to the parties hereto and may be used in lieu of the original Sixth Supplemental Indenture for all purposes. Signatures of the
parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes. 
 SECTION 3.04. GOVERNING
LAW. THIS SIXTH SUPPLEMENTAL INDENTURE AND EACH NOTE OF THE SERIES CREATED HEREUNDER SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK. 

  
 2 

 [Signature Page Follows] 

  
 3 

 IN WITNESS WHEREOF, the parties have caused this Sixth Supplemental Indenture to be duly executed by their
respective officers thereunto duly authorized as of the date first above written. 
  

					
	THE CHEMOURS COMPANY
		
	By:	 	 /s/ Sameer Ralhan

		 	Name:	  	Sameer Ralhan
		 	Title:	  	Senior Vice President and Chief Financial Officer
	
	THE CHEMOURS COMPANY FC, LLC
		
	By:	 	 /s/ Sameer Ralhan

		 	Name:	  	Sameer Ralhan
		 	Title:	  	Senior Vice President and Chief Financial Officer
	
	CHEMFIRST INC.
		
	By:	 	 /s/ Sameer Ralhan

		 	Name:	  	Sameer Ralhan
		 	Title:	  	Senior Vice President and Chief Financial Officer
	
	FIRST CHEMICAL CORPORATION
		
	By:	 	 /s/ Sameer Ralhan

		 	Name:	  	Sameer Ralhan
		 	Title:	  	Senior Vice President and Chief Financial Officer
	
	FIRST CHEMICAL TEXAS, L.P.
	By FT CHEMICAL INC., its general partner
		
	By:	 	 /s/ Sameer Ralhan

		 	Name:	  	Sameer Ralhan
		 	Title:	  	Senior Vice President and Chief Financial Officer
	
	FT CHEMICAL, INC.
		
	By:	 	 /s/ Sameer Ralhan

		 	Name:	  	Sameer Ralhan
		 	Title:	  	Senior Vice President and Chief Financial Officer
	
	FIRST CHEMICAL HOLDINGS, LLC
		
	By:	 	 /s/ Sameer Ralhan

		 	Name:	  	Sameer Ralhan
		 	Title:	  	Senior Vice President and Chief Financial Officer

  
 [Signature Page to Sixth
Supplemental Indenture] 

 
							
	U.S. BANK NATIONAL ASSOCIATION, as Trustee
			
	       	 	By:	 	 /s/ Annette Marsula

		 		 	Name:	  	Annette Marsula
		 		 	Title:	  	Vice President

  
 [Signature Page to Sixth
Supplemental Indenture]Exhibit
10.1

 

Execution
Version

 

RESTRICTED
STOCK AGREEMENT

 

This
Restricted Stock Agreement (this “Agreement”) is made effective as of August 16, 2021 (the “Effective
Date”), by and between Streamline Health Solutions, Inc., a Delaware corporation (the “Company”),
and Jawad Shaikh an individual and resident of the State of Georgia (“Shaikh”). Unless otherwise defined herein,
capitalized terms used herein shall have the meanings ascribed to them in the Unit Purchase Agreement (as defined below).

 

RECITALS

 

WHEREAS,
as part of the aggregate purchase price payable by the Company for all of the issued and outstanding units of membership interest of
Avelead Consulting, LLC, a Georgia limited liability company (“Avelead”), under that certain Unit Purchase
Agreement by and among the Company, Avelead, Shaikh, and Badar Shaikh, an individual and resident of the State of Georgia, dated as of
the Effective Date (the “Unit Purchase Agreement”), the Company agreed to issue to Shaikh certain shares of
the Company’s common stock, par value $0.01 per share (the “Common Stock”), as part of the Closing Equity
Payment, and, if earned, as part of the First Earnout Amount and the Second Earnout Amount (collectively, the “Shares”);
and

 

WHEREAS,
the Company and Shaikh acknowledge and agree that the Shares, when and if issued, shall be subject to the terms and conditions set forth
in this Agreement.

 

Now,
therefore, in consideration of the mutual covenants and
representations set forth below, the Company and Shaikh agree as follows:

 

1.
Shares. All of the Shares when and if issued shall be deemed issued to Shaikh as fully paid and non-assessable shares, and Shaikh
shall have all rights of a stockholder with respect thereto, subject to Section 2 below. The term “Shares,” in addition to
the Shares issued pursuant to the Unit Purchase Agreement, also refers to all new, substituted or additional securities received in replacement
of the Shares, as a stock dividend or as a result of any stock split, recapitalization, merger, reorganization, exchange for other securities,
by reclassification, or the like, and all new, substituted or additional securities or other properties to which Shaikh is entitled by
reason of Shaikh’s ownership of the Shares.

 

2. Restrictions.
The Shares issued to Shaikh pursuant to the terms of the Unit Purchase Agreement shall be subject, in addition to restrictions
imposed by applicable securities laws, to the following transfer restrictions:

 

2.1
(i) the Shares shall be “restricted shares” within the meaning of Regulation D and Rule 144 under the Securities Act of
1933, as amended (the “Act”), and may not be offered or sold unless such offer or sale is registered under
the Act or an exemption from registration is available; (ii) the provisions of Rule 144 under the Act shall permit resale of the
Shares only under limited circumstances and such Shares must be held by Shaikh for at least six (6) months following issuance of
such Shares before they can be resold pursuant to Rule 144 and then may be resold only in accordance with the requirements of Rule
144 (and any other applicable legal requirements); (iii) Shaikh hereby agrees to comply with the requirements of Rule 144 applicable
to affiliates of the Company (even if Shaikh is not an affiliate of the Company under the Act), that impose limitations on the
amount of securities sold in any three-month period by affiliates of the Company under Rule 144(e); and (iv) Shaikh hereby agrees to
not permit the Shares to be encumbered by any Lien (as defined in the Unit Purchase Agreement) within six (6) months following
issuance of such Shares; provided, that the restrictions in Section 2.1(iii) shall expire upon the earliest to occur
of the following events: (a) the date on which Shaikh holds less than 1% of the issued and outstanding voting securities of the
Company, on a fully diluted basis, (b) the date Shaikh’s employment with the Company or any of its affiliates is involuntarily
terminated by the Company or any of its affiliates, (c) the date Shaikh’s employment with the Company or any of its affiliates
is terminated by Shaikh for Good Reason (as such term is defined in any employment agreement between Shaikh and the Company or any
of its affiliates), (d) ninety (90) days after the date of Shaikh’s voluntary resignation of employment with the Company or
any of its affiliates, or (e) upon a Change of Control Transaction (as defined in the Unit Purchase Agreement);

 

    	 

    	 

    

 

2.2
Shaikh shall be considered a “Restricted Person” under the Company’s Insider Trading Policy (the
“Insider Trading Policy”) and shall be prohibited from conducting any sale of the Shares or any other
shares of Common Stock held by Shaikh other than during a “trading window” set forth in an email to Restricted Persons
prior to the beginning of such trading window; and the Company may, at any time, impose a “blackout” period pursuant to
the Insider Trading Policy, during which period buying, selling or otherwise transferring securities by a specified group of
insiders, which group of insiders may include Shaikh, would be considered inappropriate; provided, that the restrictions in
this Section 2.2 shall expire upon the earlier of (a) the date of termination of Shaikh’s employment with the Company
or any of its affiliates or (b) termination of the restrictions in Section 2.1(iii) above at a time when Shaikh would not
otherwise be deemed to be a “Restricted Person” under the terms of the Insider Trading Policy; and

 

2.3
Shaikh shall be prohibited from conducting any open-market sale of the Shares or any other shares of Common Stock held by
Shaikh during the thirty (30) trading days immediately prior to the last day of the First Earnout Measurement Period and Second
Earnout Measurement Period, as applicable.

 

3.
Representations and Warranties of Shaikh. In connection with the issuance of the Shares pursuant to the terms of the Unit Purchase
Agreement, Shaikh represents, warrants and acknowledges to the Company that:

 

3.1
Shaikh possesses all requisite capacity, power and authority (corporate and other) to execute and deliver this Agreement and to
perform his obligations hereunder;

 

3.2
neither the execution and delivery by Shaikh of this Agreement, nor the performance by Shaikh of his obligations hereunder will (i)
require on the part of Shaikh any notice to or filing with, or any permit, authorization, consent or approval of, any governmental
entity, or (ii) violate any order, writ, injunction, decree, statute, rule or regulation applicable to Shaikh or any of his
properties or assets, except in the cases of (i) and (ii) where any violation or failure to deliver a notice or submit a filing
would not cause a material adverse effect;

 

3.3
the Shares to be acquired by Shaikh pursuant to the Unit Purchase Agreement will be acquired for Shaikh’s own account and not
with a view to, or intention of, distribution thereof in violation of the Act, or any other applicable securities laws, and the
Shares will not be disposed of in contravention of the Act or any applicable securities laws;

 

3.4
Shaikh is an “accredited investor” within the meaning of Regulation D under the Act; and

 

3.5
the Shares are not registered under the Act on the basis that the issuance of securities hereunder is exempt from registration under
the Act pursuant to Section 4(a)(2) thereof and the rules and regulations promulgated thereunder, and that the Company’s
reliance on such exemption is predicated on Shaikh’s representations set forth herein.

 

    	2

    	 

    

 

4.
Representations and Warranties of the Company. In connection with the issuance of the Shares pursuant to the terms of the Unit
Purchase Agreement, the Company represents, warrants and acknowledges to Shaikh that:

 

4.1
the Company is a corporation duly organized, validly existing and in good standing under the laws of the state of its incorporation
and has all requisite power and authority (corporate and other) to carry on the businesses in which it is engaged and to own and use
the properties owned and used by it, and is qualified to do business and is in good standing in every jurisdiction in which the
operation of the business of the Company requires it to be so qualified;

 

4.2
the Company has all requisite capacity, power and authority (corporate or other) to execute and deliver this Agreement, to perform
its obligations hereunder, and to issue the Shares to Shaikh;

 

4.3
the execution and delivery by the Company of this Agreement, the performance by the Company of its obligations in this Agreement,
and the issuance of the Shares contemplated hereby have been duly and validly authorized by all necessary corporate and other action
on the part of the Company;

 

4.4
 neither the execution and delivery by the Company of this Agreement, nor the performance by the Company of its obligations
hereunder, nor the issuance of the Shares contemplated hereby, will (i) conflict with or violate any provision of the
Company’s articles of incorporation, by-laws, voting agreements or similar documents, instruments or agreements relating to
the organization or governance of the Company (collectively, the “Organizational Documents”), each as
amended or restated to date, (ii) require on the part of the Company any notice to or filing with, or any permit, authorization,
consent or approval of, any governmental entity, or (iii) violate any order, writ, injunction, decree, statute, rule or regulation
applicable to the Company or any of its properties or assets, except in the cases of (ii) and (iii) where any violation or failure
to deliver a notice or submit a filing would not cause a material adverse effect;

 

4.5
the Shares subject to issuance pursuant to the terms of the Unit Purchase Agreement, upon issuance on the terms and conditions
specified herein and the Unit Purchase Agreement, will be duly authorized, validly issued, fully paid and non-assessable, free and
clear of all liens and restrictions (other than restrictions on transfer imposed herein and under the Act or any other applicable
securities laws), and not subject to or issued in violation of any purchase option, call option, right of first refusal, preemptive
right, subscription right or any similar right under any provision of the Delaware General Corporation Law, the Organizational
Documents or any agreement to which the Company is a party or is otherwise bound;

 

4.6
the Company has filed all registration statements, forms, reports, certifications and other documents (collectively,
“SEC Reports”) required to be filed by the Company with the United States Securities and Exchange
Commission (the “SEC”) and all of the Company’s SEC Reports (i) have been filed on a timely basis,
(ii) at the time filed, complied as to form in all material respects with the requirements of the Act and the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), applicable to such SEC Reports, and (iii) did not, at the
time they were filed, contain any untrue statement of a material fact or omit to state a material fact required to be stated in such
SEC Reports or necessary in order to make the statements in such SEC Reports, in light of the circumstances under which they were
made, not misleading, in any material respect; and

 

4.7
the Common Stock is registered pursuant to Section 12(b) of the Exchange Act, and the Company has not (i) received any written
notification that the SEC is contemplating terminating such registration or (ii) received written notice from The NASDAQ Stock
Market LLC (“Nasdaq”) to the effect that the Company is not in compliance with the listing or maintenance
requirements of such market or exchange.

 

    	3

    	 

    

 

5. Securities
Matters. With a view to making available to Shaikh the benefits of Rule 144 under the Act and any other rule or regulation of
the SEC that may at any time permit a stockholder to sell Common Stock to the public without registration under the Act, Company
will:

 

5.1
make and keep available adequate current public information, as those terms are understood and defined in Rule 144 under the Act, at
all times after the Effective Date;

 

5.2
use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company
under the Exchange Act; and

 

5.3
furnish to Shaikh, so long as he owns at least 1% of the issued and outstanding voting securities of the Company, on a fully diluted
basis, reasonably promptly upon request (i) to the extent accurate, a written statement by the Company that it has complied with the
reporting requirements of Rule 144, the Securities Act, and the Exchange Act; and (ii) such other information as may be reasonably
requested in availing Shaikh of any rule or regulation of the SEC that permits the selling of any such securities without
registration.

 

6. Legends.
Shaikh acknowledges and agrees that the Shares shall be uncertificated and in book entry form and stop transfer instructions shall
be given to the Company’s stock transfer agent with respect to the Shares which shall be notated with the legend substantially
as follows:

 

THE
SHARES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF.
THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY
STATE SECURITIES LAWS, AND MAY NOT BE SOLD OR OFFERED FOR SALE IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES
UNDER SAID ACT OR AN EXEMPTION FROM SUCH REGISTRATION UNDER THE ACT. THE SHARES ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER AS SET
FORTH IN THAT CERTAIN RESTRICTED STOCK AGREEMENT BETWEEN THE COMPANY AND THE HOLDER.

 

7.
General Provisions.

 

7.1 Notices.
All notices, requests, demands, claims, and other communications hereunder shall be in writing (including by email). Any notice,
request, demand, claim or other communication hereunder shall be deemed duly received on the date of receipt by the recipient
thereof if received on a business day in the place of receipt prior to 5:00 p.m. Otherwise, any such notice, request or
communication shall be deemed not to have been received until the next succeeding business day in the place of receipt.

 

If
to the Company, to:

 

Streamline
Health Solutions, Inc.

11800 Amber Park Drive, Suite 125

Alpharetta, GA 30009

Attention:
Thomas J. Gibson

Email: thomas.gibson@streamlinhealth.net

 

With
a copy (which shall not constitute notice) to:

 

Morris,
Manning & Martin, LLP

3343 Peachtree Road, N.E.

1600 Atlanta Financial Center

Atlanta, Georgia 30326

Attention: David M. Calhoun

Phone: (404) 504-7613

Facsimile: (404) 365-9532

E-Mail: dmc@mmmlaw.com

 

    	4

    	 

    

  

If
to Shaikh, to:

 

P.O.
Box 839

Suwanee, GA 30024-0028

E-Mail: jwshaikh@outlook.com

 

With
a copy (which shall not constitute notice) to:

 

Kilpatrick
Townsend & Stockton LLP

1100 Peachtree Street, N.E., Suite 2800

Atlanta, GA 30309-4530

Attention: Louis Barbieri III

Phone: (404) 815-6079

Facsimile: (404) 541-3141

E-Mail: lbarbieri@kilpatricktownsend.com

 

7.2
Further Assurances. From time to time after the date hereof, upon reasonable notice and without further consideration, Shaikh
and the Company shall execute and deliver any other document or instrument and shall take any other action as may be necessary in the
reasonable discretion of the Company or any stock transfer agent to give effect to or evidence the provisions of this Agreement.

 

7.3
Assignment. Except as otherwise expressly provided herein, neither party may assign rights or delegate duties arising hereunder
without the prior written consent of the other party. Any assignment or delegation of any right, duty, or claim arising hereunder without
such consent shall be void.

 

7.4
Entire Agreement. This Agreement and the Unit Purchase Agreement constitute the exclusive statement of the agreement of the Company
and Shaikh concerning the matters set forth herein, including with respect to rights of and restrictions on the Shares and supersedes
all other agreements, oral or written, among or between any of them concerning rights of and restrictions on the Shares.Modification
and Waiver. No amendment, modification, or waiver of this Agreement shall be effective unless made in a written instrument which
specifically references this Agreement and which is signed by the Company and Shaikh. Except as expressly provided herein, the failure
of the Company or Shaikh to enforce at any time, or for any period of time, any provisions of this Agreement shall not be construed as
a waiver of any provision or of the right of any such party to enforce each and every provision of this Agreement.Binding Effect.
This Agreement shall be binding upon and inure to the benefit of Shaikh and its successors and assigns, shall be binding upon and inure
to the benefit of the Company and its successors and assigns.

 

7.5 Governing
Law. THIS AGREEMENT IS GOVERNED BY AND SHALL BE CONSTRUED IN ACCORDANCE WITH THE LAW OF THE STATE OF DELAWARE EXCLUDING ANY
CONFLICT OF LAWS RULE OR PRINCIPLE THAT MIGHT REFER THE GOVERNANCE OR THE CONSTRUCTION OF THIS AGREEMENT TO THE LAW OF ANOTHER
JURISDICTION.

 

7.6 Waiver
of Jury Trial. The parties to this Agreement each hereby waive, to the fullest extent permitted by law, any right to trial by
jury of any claim, demand, action, or cause of action (i) arising under this Agreement or (ii) in any way connected with or related
or incidental to the dealings of the parties hereto in respect of this Agreement or any of the transactions related hereto, in each
case whether now existing or hereafter arising, and whether in contract, tort, equity, or otherwise. The parties to this Agreement
each hereby agree and consent that any such claim, demand, action, or cause of action shall be decided by court trial without a jury
and that the parties to this Agreement may file an original counterpart of a copy of this Agreement with any court as written
evidence of the consent of the parties hereto to the waiver of their right to trial by jury.

 

    	5

    	 

    

 

7.7 Severability
and Reformation. If any provision of this Agreement, or the application thereof to any person or circumstance should, for any
reason and to any extent, be invalid or unenforceable, the remainder of this Agreement and the application of such provision to
other persons or circumstances shall not be affected thereby, but rather shall be enforced to the greatest extent permitted by
law.

 

7.8
Headings. The headings contained in this Agreement are intended solely for convenience of reference and shall not be considered
in interpreting this Agreement.

 

7.9
Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original, and all of which
together shall constitute one and the same instrument.

 

7.10 Third
Parties. Nothing expressed or implied in this Agreement is intended or shall be construed to confer on any person, other than
the Company and Shaikh, any rights hereunder.

 

[Signatures
on next page.]

 

    	6

    	 

    

 

IN
WITNESS WHEREOF, the parties have duly executed this Restricted Stock Agreement as of the day and year first set forth above.

 

	COMPANY:	STREAMLINE
    HEALTH SOLUTIONS, INC.
	 	 	 
	 	By:	/s/
    Thomas J. Gibson
	 	Name:	Thomas
    J. Gibson
	 	Title:	Chief
    Financial Officer
	 	 	 
	SHAIKH:	/s/ Jawad Shaikh
	 	Jawad Shaikh

 

[Signature Page to Restricted Stock Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}]]